scholarly journals Erythema multiforme-like rash as a manifestation of multisystem inflammatory syndrome in children

2021 ◽  
Vol 0 ◽  
pp. 1-3
Author(s):  
C. B. Sindhu ◽  
Babu Francis ◽  
Sandhya George ◽  
O. K. Reena Mariyath ◽  
Geetha Peethambaran ◽  
...  

Multisystem inflammatory syndrome in children (MIS-C) is a rare and serious manifestation of coronavirus disease 19 (COVID-19) infection. Skin lesions occur in more than half the cases of MIS-C. We report a 57-dayold female baby who presented with features of MIS-C with skin lesions suggestive of erythema multiforme. Her condition improved rapidly with systemic steroids and intravenous immunoglobulin G.

1990 ◽  
Vol 89 (5) ◽  
pp. 554-560 ◽  
Author(s):  
Phillip K. Peterson ◽  
Judy Shepard ◽  
Mark Macres ◽  
Carlos Schenck ◽  
John Crosson ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0139828 ◽  
Author(s):  
Willem Jan R. Fokkink ◽  
David Falck ◽  
Tom C. M. Santbergen ◽  
Ruth Huizinga ◽  
Manfred Wuhrer ◽  
...  

CNS Spectrums ◽  
1999 ◽  
Vol 4 (6) ◽  
pp. 71-77 ◽  
Author(s):  
Mark Hyman Rapaport ◽  
Cathy G. McAllister

ABSTRACTThis article presents a rationale for the hypothesis that an autoimmune mechanism might be involved in the pathogenesis of some forms of obsessive-compulsive aborder (OCO). Existing clinical studies suggesting that some individuals with OCD may have an autoimmune-mediated disorder are briefly summarized. A case example where intravenous immunoglobulin G has been successfully used to treat an adult with OCD spectrum disorder is presented. Preclinical data demonstrating that fragments from the group Αβ hemolytic streptococcus cell wall M proteins can generate antibodies that bind to rat and human tissue are also presented.


2015 ◽  
Vol 3 (9) ◽  
pp. 731-734 ◽  
Author(s):  
Sinan Tufekci ◽  
Asuman Coban ◽  
Meltem Bor ◽  
Beril Yasa ◽  
Kemal Nisli ◽  
...  

Blood ◽  
2006 ◽  
Vol 108 (3) ◽  
pp. 943-946 ◽  
Author(s):  
Michelle Lee Webster ◽  
Ebrahim Sayeh ◽  
Min Crow ◽  
Pingguo Chen ◽  
Bernhard Nieswandt ◽  
...  

Abstract Intravenous immunoglobulin G (IVIG) is used to treat idiopathic thrombocytopenic purpura (ITP). Although many patients benefit from IVIG, some are refractory to this therapy. ITP is characterized by platelet clearance mediated primarily by antiplatelet antibodies against GPIIbIIIa and/or the GPIbα complex. These 2 groups of antibodies may induce ITP through different mechanisms. We tested the hypothesis that IVIG may not be equally effective in preventing ITP caused by anti-GPIIbIIIa versus anti-GPIbα antibodies in mice. Thrombocytopenia was induced in BALB/c mice using monoclonal antibodies against either mouse GPIIbIIIa (JON1, JON2, and JON3) or GPIbα (p0p3, p0p4, p0p5, p0p9, and p0p11). Pretreatment with IVIG significantly ameliorated ITP in all anti-GPIIbIIIa–injected animals. Conversely, IVIG failed to prevent ITP in all anti-GPIbα–treated mice, except for p0p4. These results were repeated in C57BL/6 mice, and with different IVIG preparations. These data in mice suggest that patients with ITP mediated by anti-GPIbα antibodies may be less responsive to IVIG treatment.


Sign in / Sign up

Export Citation Format

Share Document